ad image

Company Info

Perrigo

Perrigo

CDMO

Overview

Perrigo Company plc is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API). From its beginnings in 1887 as a packager of generic home remedies, Perrigo, headquartered in Ireland, has grown to become the world's largest manufacturer of OTC products and supplier of infant formulas for the store brand market.
Perrigo
Contributions
13 Contributions1 / 1
Perrigo
FDA Approval

Perrigo and Catalent Announce FDA Approval of Perrigo's AB-Rated Generic Version of ProAir® HFA

Perrigo

PR-M02-20-NI-041Feb 27, 2020
Perrigo
Finance

Perrigo Increases Its Dividend By 11%

Perrigo

PR-M04-19-NI-090Apr 30, 2019
Perrigo
Milestone Payment

Perrigo To Receive Milestone Payment Of $250 Million From RPI Finance Trust

Perrigo

PR-M01-19-NI-095Feb 01, 2019
Perrigo
Appointment

Perrigo Appoints James Dillard To Role Of Chief Scientific Officer

Perrigo

PR-M01-19-NI-044-3142Jan 16, 2019
Perrigo
FDA Approval

Perrigo Announces Tentative FDA Approval for the First To file Generic Version Of Ultravate® Lotion 0.05%

Perrigo

PR-M11-18-NI-107Nov 30, 2018
Perrigo
Launch

Perrigo Launches Its AB Rated Generic Version of Solaraze® Gel 3%

Perrigo

PR-M11-18-NI-100-3329Nov 28, 2018
Perrigo
Patent

Perrigo Confirms Patent Challenge For Generic Version Of Kerydin®

Perrigo

PR-M11-18-NI-008Nov 02, 2018
Perrigo
Financial Results

Perrigo To Release Third Quarter Calendar Year 2018 Financial Results On November 8, 2018

Perrigo

PR-M10-18-NI-097Oct 29, 2018
Perrigo
Growth Strategy

Perrigo Expands OTC Growth Strategy With Rx-To-OTC Switch Licensing For Nasonex®

Perrigo

PR-M08-18-NI-117Aug 30, 2018
Perrigo
Launch

Perrigo Launches Novel Omeprazole Orally Disintegrating Tablet to Treat Frequent Heartburn

Perrigo

PR-M04-18-NI-50Apr 16, 2018
Perrigo
FDA

Perrigo Announces Final FDA Approval and Planned Launch for the Store Brand OTC Equivalent of Mucinex® DM Maximum Strength Extended Release Tablets

Perrigo

PR-M03-18-NI-037-4609Mar 09, 2018
Perrigo
Appointment

Perrigo Appoints Ronald L. Winowiecki as Chief Financial Officer

Perrigo

PR-M02-18-NI-89Feb 23, 2018
Perrigo
Generics

Perrigo Confirms Patent Challenge For Generic Version Of Finacea® Foam, 15%

Perrigo

PR-M02-18-NI-90Feb 23, 2018
1 / 1
0 Contributors1 / 0

No authors found

1 / 0